Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Siemens Healthineers lays solid foundation for fiscal year 2024 with strong growth in first quarter
Press release

Siemens Healthineers lays solid foundation for fiscal year 2024 with strong growth in first quarter

Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2024 ended December 31, 2023.

Published on February 1, 2024

Q1 Fiscal Year 2024

  • Very good equipment book-to-bill ratio of 1.14 
  • Strong comparable revenue growth of 7.0% excluding rapid COVID-19 antigen tests; comparable revenue growth of 5.7% including the rapid antigen-test business, which ended in the fourth quarter of fiscal year 2023 
  • Imaging comparable revenue growth of 5.3%; adjusted EBIT margin of 19.1% due to a temporary unfavorable business mix 
  • Diagnostics comparable revenue growth of 1.6% excluding rapid COVID-19 antigen tests; comparable revenue declined by 4.0% including the now-ended rapid antigen-test business; adjusted EBIT margin of 5.1% 
  • Varian sharp comparable revenue growth of 22.3%; adjusted EBIT margin of 15.9% 
  • Advanced Therapies comparable revenue growth of 5.0%; adjusted EBIT margin of 14.3% 
  • Overall adjusted EBIT margin of 14.3% was above prior-year quarter 
  • Adjusted basic earnings per share of €0.49

Outlook for Fiscal Year 2024

We confirm our expectation of comparable revenue growth of between 4.5% and 6.5% (between 5.0% and 7.0% excluding revenue from rapid COVID-19 antigen tests) and adjusted basic earnings per share of between €2.10 and €2.30. 

Bernd Montag, CEO of Siemens Healthineers AG:

»We had a good start to the new financial year with broad-based growth. The transformation of our Diagnostics business is showing positive momentum and Varian delivered strong results. In parallel we are focused on our new, ambitious sustainability goals.«

Download Quarterly Statement(pdf, 239.18 KB)

Siemens Healthineers 2024

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2023, which ended on September 30, 2023, Siemens Healthineers had approximately 71,000 employees worldwide and generated revenue of around €21.7 billion. Further information is available at www.siemens-healthineers.com.